Q1 2026 Compugen Ltd Earnings Call Transcript
Key Points
- Compugen Ltd (CGEN) is making significant progress with its fully owned clinical program, COM701, which has shown promising results in ovarian cancer treatment.
- The company has initiated the MAIA-ovarian adaptive platform trial to test COM701 as a maintenance therapy, with active patient enrollment across the United States, Israel, and France.
- Compugen Ltd (CGEN) has a solid financial position with a cash runway expected to last into 2029, providing stability and flexibility for future developments.
- Partnership with AstraZeneca is progressing well, with multiple abstracts presented at the AACR Annual Meeting, reinforcing confidence in the rilvegostomig program.
- The Unigen discovery engine continues to be a valuable asset, having already discovered targets for COM701, COM902, and GS-0321, and is expected to identify more innovative programs.
- Revenues for the first quarter of 2026 were slightly lower than the comparable period in 2025, indicating potential challenges in revenue growth.
- Research and development expenses have increased, primarily due to higher clinical expenses related to the MAIA-ovarian trial and drug supply costs.
- The net loss for the first quarter of 2026 increased compared to the same period in 2025, reflecting ongoing financial challenges.
- The MAIA-ovarian trial is exploratory, and the full magnitude of benefit from COM701 is still uncertain, with benchmarks for control arm PFS ranging widely.
- There is no specific timeline or guidelines for disclosing future development candidates from the Unigen platform, which may lead to uncertainty about pipeline progress.
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's first quarter 2026 results conference call. (Operator Instructions) An audio webcast of this call is available in the Investors section of Compugen's website at www.cgen.com. As a reminder, today's call is being recorded.
I will now hand the call over to Lindsey Trickett, Head of Investor Relations and Corporate Communications to begin. Lindsey, please go ahead.
Thank you, operator. Good morning and good afternoon, everyone, and welcome to Compugen's First Quarter 2026 Financial Results Conference Call. With us today are Dr. Eran Ophir, President and Chief Executive Officer; and David Silberman, Chief Financial Officer. Dr. Michelle Mahler, Chief Medical Officer, will join us for the Q&A portion of the call.
Before we begin, I'd like to remind you that during this call, the company may make projections or forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
